Full Press Release Details
NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36thAnnual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026.
36thAnnual Oppenheimer Healthcare Life Sciences ConferenceFormat: Virtual presentation and one-on-one investor meetingsDate: February 25, 2026Presentation Time: 3:20pm Eastern TimeWebcast Link:Click Here
About CorbusCorbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells; and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visitcorbuspharma.com. Connect with us onX,LinkedInandFacebook.